Acromegaly  >>  Somatuline Depot (lanreotide prolonged-release subcutaneous)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
NCT02396953 / 2014-002389-62: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Completed
2a
28
Europe, RoW
Lanreotide PRF, Lanreotide acetate
Ipsen
Acromegaly
11/17
11/17
NCT00517491: Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

Withdrawn
2
0
RoW
lanreotide (Autogel formulation)
Ipsen
Acromegaly
12/08
12/08
2005-004300-36: Use of somatostatin analogue therapy as primary medical treatment of acromegaly

Ongoing
2
10
Europe
Somatuline Autogel, Somatuline Autogel 60mg, Somatuline Autogel 90mg, Somatuline Autogel 120mg, Somatuline Autogel 60mg, Somatuline Autogel 90mg, Somatuline Autogel 120mg
Plymouth Hospital NHS Trust, R&D dept
Acromegaly
 
 
ACROBAT EVOLVE, NCT03792555 / 2018-001833-42: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

Completed
2
13
Europe, US, RoW
Paltusotine, CRN00808, Placebo
Crinetics Pharmaceuticals Inc.
Acromegaly
07/20
08/20
NCT03967249 / 2019-000591-42: Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

Completed
2
39
Europe, US, RoW
IONIS GHR-LRx, Somatostatin Receptor Ligand (SRL), lanreotide, octreotide
Ionis Pharmaceuticals, Inc.
Acromegaly
03/22
07/22

Download Options